Inflammatory biomarkers as differential predictors of antidepressant response

Although antidepressants are generally effective in the treatment of major depressive disorder (MDD), it can still take weeks before patients feel the full antidepressant effects. Despite the efficacy of standard treatments, approximately two-thirds of patients with MDD fail to respond to pharmacoth...

Full description

Saved in:
Bibliographic Details
Published inInternational Journal of Molecular Sciences Vol. 16; no. 4; pp. 7796 - 7801
Main Author Hashimoto, Kenji
Format Journal Article Book Review
LanguageEnglish
Published Switzerland MDPI AG 08.04.2015
MDPI
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Although antidepressants are generally effective in the treatment of major depressive disorder (MDD), it can still take weeks before patients feel the full antidepressant effects. Despite the efficacy of standard treatments, approximately two-thirds of patients with MDD fail to respond to pharmacotherapy. Therefore, the identification of blood biomarkers that can predict the treatment response to antidepressants would be highly useful in order to improve this situation. This article discusses inflammatory molecules as predictive biomarkers for antidepressant responses to several classes of antidepressants, including the N-methyl-d-aspartate (NMDA) receptor antagonist ketamine.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ObjectType-Article-1
ObjectType-Feature-2
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms16047796